LCFA and IASLC Award $400,000 to Early-Career Researchers to Combat Lung Cancer

In a significant move to accelerate lung cancer research, the Lung Cancer Foundation of America (LCFA) and the International Association for the Study of Lung Cancer (IASLC) have announced $400,000 in funding to two early-career investigators. The grants, each worth $200,000, are part of the Early Career Researcher (ECR) grant program, which aims to provide crucial support to promising scientists at a pivotal stage in their careers.

The funding comes at a time when lung cancer remains the leading cause of cancer deaths worldwide, claiming a life in the United States every 4.2 minutes. Despite advances in treatment, the disease's complexity and resistance to therapy continue to pose significant challenges. The two selected projects address these challenges head-on: one focusing on the role of lung microbiota in cancer development, and the other on metabolic pathways that enable drug resistance.

Dr. Jared Mayers of Fred Hutch Cancer Center is investigating the influence of naturally occurring bacteria in the lungs on cancer formation. Because these microbes exist in minute quantities, they have been difficult to study. Dr. Mayers is developing highly sensitive techniques to capture and analyze these bacteria within lung tissue, aiming to map their contributions to cancer and uncover new prevention strategies. His motivation is rooted in the belief that "we don't get new drugs, we don't get new therapies, we don't get longer lives, better quality lives, more time with family unless we invest in the upfront groundwork."

Dr. Jaime L. Schneider of Dana-Farber Cancer Institute is focusing on how lung cancer cells adapt to survive treatment. She is decoding the metabolic changes that allow cancer cells to become resistant to chemotherapy and targeted therapies. By identifying weak points in this adaptive system, her research aims to design more effective treatments that prevent resistance, offering hope for patients with advanced disease. Dr. Schneider was drawn to thoracic oncology by the "tremendous arsenal of new drugs that had just come out that were really changing patient lives."

The ECR grant program has a proven track record of generating significant returns. According to LCFA, the program has awarded 25 grants totaling $4.6 million, which have leveraged an additional $50 million in subsequent funding from other organizations—a 13-fold return on investment. This "multiplier effect" underscores the importance of early-stage funding in advancing research.

Kim Norris, co-founder and president of LCFA, emphasized the necessity of supporting early-career investigators: "By investing in these researchers, we are accelerating the pace of discovery and ensuring that promising ideas in metabolic tracking and drug resistance can move from the laboratory to the clinic, where they are needed most."

The grants are part of a month-long observance of World Lung Cancer Day, highlighting the ongoing urgency to improve outcomes for patients. For more information about the researchers and their work, visit LCFA's Meet the Researcher page. The investment underscores the commitment of LCFA and IASLC to fostering innovation that can translate into life-saving treatments.